Category Archives: Business and Investments

Latest From Business and Investments

2015: A Promising Year for Biotech Jobs

BIO_Career_Fair

If you’re in the biotech sector and are looking for a new career, you’re in luck: according to a recent survey by BioSpace, 70% of respondents believe new jobs will be on the horizon this year. The majority of respondents say that small firms will lead the hiring rush. The poll was split over where most hiring would occur, with 39% believing it would go to research and development jobs, and 39% believing it would Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Innovation Files: CSBI Tax Proposals Attempt to Bridge “Valley of Death”

CSBI-logo

Over at the Innovation Files, Joe Kennedy has posted an excellent summary of a set of tax reform proposals developed by the Coalition of Small Business Innovators (CSBI), of which BIO is a member. The proposals would increase investment and employment at small, research intensive companiesby allowing investors to take advantage of passive losses and research credits generated by the company. They would also allow companies to carry net operating losses forward to future years Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

72263479

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, The Bio Report. Dave discussed BIO‘s Venture Funding of Therapeutic Innovation Report, of which he is the lead author. The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO’s Next Generation Partnering System to Open April 2015

partnering-HP-300x312

You’ve found your lead investor. Now it’s time to get to the next stage, and the best place to do so is the 2015 BIO International Convention. You have a meeting with Pfizer at 9:00 a.m. followed by a meeting with AstraZeneca/MedImmune at 9:30 a.m. Then a 30 minute break. Then you have four meetings back to back with Sofinnova, Takeda Ventures, Gates Foundation and Merck. After a quick lunch it’s back to partnering: make Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Perfect Close

72263479

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,